KYMR
Kymera Therapeutics Inc.
Company Overview
| Mkt Cap | $4.63B | Price | $66.04 |
| Volume | 768.95K | Change | +2.18% |
| P/E Ratio | -20.7 | Open | $64.04 |
| Revenue | $47.1M | Prev Close | $64.63 |
| Net Income | $-223.9M | 52W Range | $19.45 - $68.46 |
| Div Yield | N/A | Target | $76.14 |
| Overall | 61 | Value | 60 |
| Quality | -- | Technical | 63 |
No chart data available
About Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest News
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and SurModics (SRDX)
B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYMR | $66.04 | +2.2% | 768.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kymera Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW